Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.30 |
| ▸ | TUBB | P07437 | 3/20 | 0.30 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.30 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.30 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.30 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.30 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.30 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.30 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.30 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.30 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.30 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.30 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.30 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.30 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12506120 | 0.81 | PRMT5 (0.32) | PRMT5 | |
| SCHEMBL30774335 | 0.78 | TUBB4A (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30677346 | 0.77 | IRAK4 (0.33) | CDK1 | |
| SCHEMBL19661033 | 0.77 | GRM2 (0.35) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12266113 | 0.77 | PSMB8 (0.40) | PSMB8 | |
| SCHEMBL24074319 | 0.76 | — | — | |
| SCHEMBL18359327 | 0.76 | CYP19A1 (0.33) | — | |
| SCHEMBL16484167 | 0.74 | GRIN2B (0.36) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL20996054 | 0.73 | HTR6 (0.34) | — | |
| SCHEMBL20996051 | 0.73 | NOTUM (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2024233605-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-116178374-B | Small-conductance calcium-activated potassium ion channel agonist, synthesis and application thereof | 河北医科大学 | 2024-10-08 | — | — | CN | disclosed |
| CN-117624063-A | Heterocyclic compound and application thereof | 中国科学院上海药物研究所 | 2024-03-01 | — | — | CN | disclosed |
| EP-4313308-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024014885-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-18 | — | — | WO | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| EP-4223761-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| CN-116178374-A | Small-conductance calcium-activated potassium ion channel agonist, synthesis and application thereof | 河北医科大学 | 2023-05-30 | — | — | CN | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | INTRABIOTICS PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
| US-20080267887-A1 | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds | NEUROGEN CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1957495-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-08-20 | — | — | EP | disclosed |
| EP-1956009-A1 | AROMATIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1956009-A1 | AROMATIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007064045-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | PRMT5 2205/4885PSMB8 2994/4885SMN1; SMN2 3369/4885 |
| US-20080267887-A1 | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds | C5AR1, C5AR2, C3AR1 | PRMT5 804/4885PSMB8 3016/4885SMN1; SMN2 4820/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | PRMT5 883/4885PSMB8 2043/4885SMN1; SMN2 2665/4885 |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | PNP, TPMT, DUT | PRMT5 485/4885PSMB8 2363/4885SMN1; SMN2 3886/4885 |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, SRC | PRMT5 926/4885PSMB8 2813/4885SMN1; SMN2 3850/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | PRMT5 2696/4885PSMB8 2425/4885SMN1; SMN2 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.